Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:18 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Comparison of Insulin Detemir and NPH Insulin Given Once Daily in Ageing Subjects With Type 2 Diabetes
NCT00506662 · Novo Nordisk A/S · PHASE4 · terminated · last registry update 2023-08-14 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “See termination reason in detailed description” | – | Registry record, Novo Nordisk A/S |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against INSR within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-07-29Results posted on the registry: The Cleveland Clinic, Semaglutide + Insulin Degludec (NCT04538352)
- 2024-04-02Phase 3 first posted: Novo Nordisk A/S, Insulin icodec + Insulin glargine (NCT06340854)
- 2024-03-20Results posted on the registry: Novo Nordisk A/S, Faster aspart + Insulin aspart (NCT04588259)
- 2024-02-28Results posted on the registry: University of Washington, Insulin Degludec + Insulin Glargine (NCT04623086)
- 2024-02-21Phase 3 first posted: Novo Nordisk A/S, IcoSema + Insulin glargine (NCT06269107)
- 2024-02-21Also stopped (terminated): Centre Hospitalier Universitaire Dijon, LEVEMIR + APIDRA (NCT02048189)
- 2024-01-24Results posted on the registry: University at Buffalo, Dapagliflozin + Insulin (NCT02518945)
- 2023-11-02Also stopped (terminated): Charles Drew University of Medicine and Science, Insulin glargine at bedtime instead of NPH + NPH twice-daily (NCT00687453)
- 2023-11-01Phase 3 first posted: Sling Therapeutics, Inc., linsitinib (NCT06112340)
- 2023-09-18Results posted on the registry: Corewell Health West, insulin glulisine + insulin aspart (NCT00913497)
- 2023-09-08Results posted on the registry: Emory University, IDegLira + Insulin Degludec (U-100) (NCT03737240)
- 2023-04-21Phase 3 first posted: Novo Nordisk A/S, Insulin Icodec (NCT05823948)
- 2023-04-14Phase 3 first posted: Novo Nordisk A/S, Insulin Icodec + Semaglutide (NCT05813912)
- 2023-04-07Phase 3 first posted: Sunshine Lake Pharma Co., Ltd., Insulin Degludec and Insulin Aspart (NCT05802862)
- 2023-03-14Phase 3 first posted: Hospital Universitario San Ignacio, insulin degludec + liraglutide + Insulin Glargine - Insulin Aspart (NCT05767255)
- 2023-02-08Results posted on the registry: Eli Lilly and Company, LY900014 + Insulin Lispro (NCT03952130)
- 2022-12-07Phase 3 first posted: Huashan Hospital, Insulin Degludec and Insulin Aspart (NCT05641337)
- 2022-11-14Results posted on the registry: Sanofi, Insulin glargine, 300 U/ml + Insulin degludec, 100U/ml (NCT04075513)
- 2022-11-02Results posted on the registry: Eli Lilly and Company, LY3209590 + Insulin Degludec (NCT04450394)
- 2022-10-27Results posted on the registry: Eli Lilly and Company, LY3209590 + Insulin Degludec (NCT04450407)
- 2022-10-04Phase 3 first posted: Jaime Daniel Mondragon, Dapagliflozin 10mg Tab + Statins (Cardiovascular Agents) (NCT05565976)
- 2022-09-19Phase 3 first posted: Xiangya Hospital of Central South University, metformin+empagliflozin+insulin glargine + IDegLira (NCT05545800)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision